Pneumonia risk in COPD patients initiating extrafine Fixed Dose Combination (FDC) with beclometasone dipropionate (ef-FDC-BDP) versus long-acting bronchodilators (LABD)

David Price; William  Henley; Victoria Carter; Derek Skinner; Rebecca  Vella; Alberto Papi; Leonardo M Fabbri; Huib AM  Kerstjens; Nicolas Roche; Dave  Singh; Claus F Vogelmeier; Elif  Şen; José Eduardo  Delfini Cançado; Elena  Nudo; Sara  Barile; George  Georges

Pneumonia risk in COPD patients initiating extrafine Fixed Dose Combination (FDC) with beclometasone dipropionate (ef-FDC-BDP) versus long-acting bronchodilators (LABD)

David Price, William Henley, Victoria Carter, Derek Skinner, Rebecca Vella, Alberto Papi, Leonardo M Fabbri, Huib AM Kerstjens, Nicolas Roche, Dave Singh, Claus F Vogelmeier, Elif Şen, José Eduardo Delfini Cançado, Elena Nudo, Sara Barile, George Georges

Research output: Contribution to conference › Abstract › peer-review

Abstract

Background: The use of extrafine inhaled corticosteroid (ICS) formulations in COPD
treatment reduce exacerbations and allow lower doses possibly reducing pneumonia risk.

Original language	English
Publication status	Accepted/In press - 29 Jul 2021
Event	ERS International Congress 2021 - Virtual event Duration: 5 Sep 2021 → 8 Sep 2021 https://www.ersnet.org/congress-and-events/congress/

Conference

Conference	ERS International Congress 2021
Abbreviated title	ERS
Period	5/09/21 → 8/09/21
Internet address	https://www.ersnet.org/congress-and-events/congress/

Cite this

Price, D., Henley, W., Carter, V., Skinner, D., Vella, R., Papi, A., Fabbri, L. M., Kerstjens, H. AM., Roche, N., Singh, D., Vogelmeier, C. F., Şen, E., Delfini Cançado, J. E., Nudo, E., Barile, S., & Georges, G. (Accepted/In press). Pneumonia risk in COPD patients initiating extrafine Fixed Dose Combination (FDC) with beclometasone dipropionate (ef-FDC-BDP) versus long-acting bronchodilators (LABD). Abstract from ERS International Congress 2021.

Price, D, Henley, W, Carter, V, Skinner, D, Vella, R, Papi, A, Fabbri, LM, Kerstjens, HAM, Roche, N, Singh, D, Vogelmeier, CF, Şen, E, Delfini Cançado, JE, Nudo, E, Barile, S & Georges, G 2021, 'Pneumonia risk in COPD patients initiating extrafine Fixed Dose Combination (FDC) with beclometasone dipropionate (ef-FDC-BDP) versus long-acting bronchodilators (LABD)', ERS International Congress 2021, 5/09/21 - 8/09/21.

@conference{c89e8b0212dd44458d8b884fc0cf047c,

title = "Pneumonia risk in COPD patients initiating extrafine Fixed Dose Combination (FDC) with beclometasone dipropionate (ef-FDC-BDP) versus long-acting bronchodilators (LABD)",

abstract = "Background: The use of extrafine inhaled corticosteroid (ICS) formulations in COPDtreatment reduce exacerbations and allow lower doses possibly reducing pneumonia risk.",

author = "David Price and William Henley and Victoria Carter and Derek Skinner and Rebecca Vella and Alberto Papi and Fabbri, {Leonardo M} and Kerstjens, {Huib AM} and Nicolas Roche and Dave Singh and Vogelmeier, {Claus F} and Elif {\c S}en and {Delfini Can{\c c}ado}, {Jos{\'e} Eduardo} and Elena Nudo and Sara Barile and George Georges",

year = "2021",

month = jul,

day = "29",

language = "English",

note = "ERS International Congress 2021, ERS ; Conference date: 05-09-2021 Through 08-09-2021",

url = "https://www.ersnet.org/congress-and-events/congress/",

}

TY - CONF

T1 - Pneumonia risk in COPD patients initiating extrafine Fixed Dose Combination (FDC) with beclometasone dipropionate (ef-FDC-BDP) versus long-acting bronchodilators (LABD)

AU - Price, David

AU - Henley, William

AU - Carter, Victoria

AU - Skinner, Derek

AU - Vella, Rebecca

AU - Papi, Alberto

AU - Fabbri, Leonardo M

AU - Kerstjens, Huib AM

AU - Roche, Nicolas

AU - Singh, Dave

AU - Vogelmeier, Claus F

AU - Şen, Elif

AU - Delfini Cançado, José Eduardo

AU - Nudo, Elena

AU - Barile, Sara

AU - Georges, George

PY - 2021/7/29

Y1 - 2021/7/29

N2 - Background: The use of extrafine inhaled corticosteroid (ICS) formulations in COPDtreatment reduce exacerbations and allow lower doses possibly reducing pneumonia risk.

AB - Background: The use of extrafine inhaled corticosteroid (ICS) formulations in COPDtreatment reduce exacerbations and allow lower doses possibly reducing pneumonia risk.

M3 - Abstract

T2 - ERS International Congress 2021

Y2 - 5 September 2021 through 8 September 2021

ER -

Pneumonia risk in COPD patients initiating extrafine Fixed Dose Combination (FDC) with beclometasone dipropionate (ef-FDC-BDP) versus long-acting bronchodilators (LABD)

Abstract

Conference

Fingerprint

Cite this